LncRNA PVT1 induces aggressive vasculogenic mimicry formation through activating the STAT3/Slug axis and epithelial-to-mesenchymal transition in gastric cancer DOI
Jing Zhao, Jing Wu,

Yunyun Qin

и другие.

Cellular Oncology, Год журнала: 2020, Номер 43(5), С. 863 - 876

Опубликована: Июль 29, 2020

Язык: Английский

lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions DOI
Evan M. McCabe, Theodore P. Rasmussen

Seminars in Cancer Biology, Год журнала: 2020, Номер 75, С. 38 - 48

Опубликована: Дек. 18, 2020

Язык: Английский

Процитировано

243

MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting DOI
Asif Ahmad Bhat, Obaid Afzal, Muhammad Afzal

и другие.

Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 154991 - 154991

Опубликована: Ноя. 30, 2023

Язык: Английский

Процитировано

74

Hallmarks of cancer resistance DOI Creative Commons
Muhammad Tufail,

Jia-Ju Hu,

Jie Liang

и другие.

iScience, Год журнала: 2024, Номер 27(6), С. 109979 - 109979

Опубликована: Май 15, 2024

This review explores the hallmarks of cancer resistance, including drug efflux mediated by ATP-binding cassette (ABC) transporters, metabolic reprogramming characterized Warburg effect, and dynamic interplay between cells mitochondria. The role stem (CSCs) in treatment resistance regulatory influence non-coding RNAs, such as long RNAs (lncRNAs), microRNAs (miRNAs), circular (circRNAs), are studied. chapter emphasizes future directions, encompassing advancements immunotherapy, strategies to counter adaptive integration artificial intelligence for predictive modeling, identification biomarkers personalized treatment. comprehensive exploration these provides a foundation innovative therapeutic approaches, aiming navigate complex landscape enhance patient outcomes.

Язык: Английский

Процитировано

26

Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer DOI

Wangkai Xie,

Man Chu,

Gendi Song

и другие.

Seminars in Cancer Biology, Год журнала: 2020, Номер 83, С. 303 - 318

Опубликована: Ноя. 15, 2020

Язык: Английский

Процитировано

96

Epitranscriptomic Signatures in lncRNAs and Their Possible Roles in Cancer DOI Open Access
Sorina Dinescu,

Simona Ignat,

Andreea Daniela Lazăr

и другие.

Genes, Год журнала: 2019, Номер 10(1), С. 52 - 52

Опубликована: Янв. 16, 2019

In contrast to the amazing exponential growth in knowledge related long non-coding RNAs (lncRNAs) involved cell homeostasis or dysregulated pathological states, little is known so far about links between chemical modifications occurring lncRNAs and their function. Generally, ncRNAs are post-transcriptional regulators of gene expression, but RNA generate an additional layer expression control. Chemical that have been reported correlation with include m6A, m5C pseudouridylation. Up date, several chemically modified transcripts identified associated different pathologies, including cancers. This review presents current level on most studied cancer-related lncRNAs, such as metastasis lung adenocarcinoma transcript 1 (MALAT1), Hox antisense intergenic (HOTAIR), X-inactive specific (XIST), well more recently discovered forms, potential roles types cancer. Understanding how these occur, lncRNA changes structure function, may open up new therapeutic possibilities

Язык: Английский

Процитировано

91

The emerging role of noncoding RNAs in colorectal cancer chemoresistance DOI
Ling Wei,

Xingwu Wang,

Liyan Lv

и другие.

Cellular Oncology, Год журнала: 2019, Номер 42(6), С. 757 - 768

Опубликована: Июль 29, 2019

Язык: Английский

Процитировано

89

Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma DOI Creative Commons

YANG Liuqing,

Jinling Yu,

Tao Lu

и другие.

Frontiers in Genetics, Год журнала: 2022, Номер 13

Опубликована: Июль 22, 2022

Background: Cuproptosis is a new type of cell death that induces protein toxic stress and eventually leads to death. Hence, regulating cuproptosis in tumor cells therapeutic approach. However, studies on cuproptosis-related long noncoding RNA (lncRNA) head neck squamous carcinoma (HNSC) have not been found. This study aimed explore the lncRNAs prognostic marker their relationship immune microenvironment HNSC by using bioinformatics methods. Methods: sequencing, genomic mutations, clinical data TCGA_HNSC were downloaded from The Cancer Genome Atlas. patients randomly assigned either training group or validation cohort. least absolute shrinkage selection operator Cox regression multivariate models used determine model cohort, its independent effect was further confirmed entire cohorts. Results: Based previous literature, we collected 19 genes associated with cuproptosis. Afterward, 783 obtained through coexpression. revealed constructed eight (AL132800.1, AC090587.1, AC079160.1, AC011462.4, AL157888.1, GRHL3-AS1, SNHG16, AC021148.2). Patients divided into high- low-risk groups based median risk score. Kaplan-Meier survival curve overall between statistically significant. receiver operating characteristic principal component analysis demonstrated accurate ability model. Univariate showed score an factor. In addition, establish nomogram predictive power markers. mutation burden significant differences groups. high-risk responded better immunotherapy than those group. We also found scores significantly drug sensitivity HNSC. Conclusion: summary, our identified cuprotosis-related signature as predictor, which may be promising biomarkers for predicting benefit well sensitivity.

Язык: Английский

Процитировано

69

Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer DOI
Fatemeh Davodabadi, Shekoufeh Mirinejad, Sumira Malik

и другие.

Nanoscale, Год журнала: 2024, Номер 16(8), С. 3881 - 3914

Опубликована: Янв. 1, 2024

The long noncoding RNAs (lncRNAs) comprise a wide range of RNA species whose length exceeds 200 nucleotides, which regulate the expression genes and cellular functions in organisms.

Язык: Английский

Процитировано

13

MALAT-1 Is a Key Regulator of Epithelial–Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis DOI Open Access
Mohamed Ali Hussein,

Kamyab Valinezhad,

Eman Adel

и другие.

Cancers, Год журнала: 2024, Номер 16(1), С. 234 - 234

Опубликована: Янв. 4, 2024

Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long intergenic non-coding RNA (lncRNA) located on chr11q13. It overexpressed in several cancers and controls gene expression through chromatin modification, transcriptional regulation, post-transcriptional regulation. Importantly, MALAT-1 stimulates cell proliferation, migration, metastasis serves vital role driving the epithelial-to-mesenchymal transition (EMT), subsequently acquiring cancer stem cell-like properties developing drug resistance. modulates EMT by interacting with various intracellular signaling pathways, notably phosphoinositide 3-kinase (PI3K)/Akt Wnt/β-catenin pathways. also behaves like sponge for microRNAs, preventing their interaction target genes promoting EMT. In addition, we have used bioinformatics online tools to highlight disparities of between normal samples using data from The Cancer Genome Atlas (TCGA). Furthermore, intricate interplay essential targets progression renders it good candidate therapeutic interventions. Several innovative approaches been exploited MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), natural products. This review emphasizes modulating metastasis, stemness, chemoresistance different cancers.

Язык: Английский

Процитировано

12

Evidence for ligandable sites in structured RNA throughout the Protein Data Bank DOI

William M. Hewitt,

David Calabrese, John S. Schneekloth

и другие.

Bioorganic & Medicinal Chemistry, Год журнала: 2019, Номер 27(11), С. 2253 - 2260

Опубликована: Апрель 6, 2019

Язык: Английский

Процитировано

77